Protara Therapeutics (TARA) launched a public offering of common shares.
Underwriters are expected to get a 30-day overallotment option for additional shares at the offering price, Protara said Monday in a statement.
Net proceeds are expected to fund the clinical development of TARA-002, among other things, the company said.
TARA-002 is an investigational cell therapy in development for the treatment of nonmuscle invasive bladder cancer and lymphatic malformations.
Protara's shares fell 8.7% in recent after-hours activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。